Contineum Therapeutics Inc

CTNMNASDAQ · USD
13.56USD+0.35 (+2.65%)
259

Contineum Therapeutics Inc (CTNM) Wheel Strategy

CTNM wheel strategy scan found 10 cash-secured put setups on the previous trading day. Probability of expiring worthless is above 50%. Annualized returns reach up to 198.4%.

Read more

Running a CTNM wheel strategy lets you generate consistent premium income on Contineum Therapeutics Inc while setting your own entry and exit prices on the underlying. Contineum Therapeutics Inc's wheel combines cash-secured puts and covered calls into a repeatable cycle: sell puts at strikes where you'd be happy to own CTNM, and if assigned, sell calls at strikes where you'd be happy to sell. Use our scanner to find the best CTNM wheel strategy setups in real time.

The wheel works best on liquid, high-quality names with stable fundamentals and active options markets — exactly the profile many large-cap leaders fit. The mechanics are simple: sell a cash-secured put on CTNM, collect premium, and either keep the premium if it expires worthless or take assignment at a discount to current price. Once assigned, sell covered calls against the shares to keep collecting premium until they're called away. Choosing the right strikes, expirations, and IV environment is what separates a profitable CTNM wheel from a losing one.

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.

Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

The difference between a wheel that compounds and one that bleeds comes down to strike selection, IV timing, and discipline on assignment. Our scanner handles the heavy lifting: it ranks every leg of the CTNM wheel strategy by delta, premium yield, IV rank, and days to expiration, so you can deploy capital where the math works. Build your CTNM wheel strategy on data, not gut feel — and let the options wheel do what it does best: pay you to wait.

Dec 18, 20265.00$0.10$2.50-0.07922%95.9%198.4%0
Nov 20, 20267.50$0.10$2.50-0.14642%88.2%190.1%10
Jan 15, 20275.00$0.20$2.55-0.071202%92.8%155.1%0
Nov 20, 202610.00$0.25$2.58-0.22642%68.7%146.9%10
Dec 18, 202610.00$1.00$3.25-0.21922%63.2%128.9%2
Dec 18, 20267.50$0.10$2.25-0.14922%82.1%119.0%5
Jan 15, 202710.00$1.70$3.85-0.201202%59.3%117.1%3,528
Jan 15, 20277.50$0.45$2.63-0.141202%77.2%106.5%11
Apr 16, 202710.00$1.50$3.65-0.202112%51.2%63.1%0
Apr 16, 20277.50$0.80$2.40-0.142112%66.0%55.4%0

As of September 17, 2026

Run the Wheel on CTNM With Confidence

Find the best CTNM wheel strategy setups across strikes and expirations, plan ahead with at-strike values, and keep your covered calls and puts on track.

Start your 14-day free trial